Literature DB >> 11886525

Appearance of Langerhans cells in the epidermis of Tgfb1(-/-) SCID mice: paracrine and autocrine effects of transforming growth factor-beta 1 and -beta 2(1).

R M Thomas1, D V Belsito, C Huang, L Z Chen Lz, I Ormsby, W J Simmons, P Cowin, J Shaw, T Doetschman, G J Thorbecke.   

Abstract

A striking immunologic abnormality of normal and SCID Tgfb1(-/-) mice is the total absence of Langerhans cells in their epidermis. Here we show that transfer of Tgfb1(+/-) SCID bone marrow causes, within a few weeks, the appearance of Langerhans cells in the epidermis of gamma-irradiated and unirradiated Tgfb1(-/-) SCID recipients. In addition, local injection of 2 x 10(5) latent transforming growth factor-beta1 cDNA-transduced cloned CD4+ T lymphocytes causes the appearance of Langerhans cells in the ear epidermis of Tgfb1(-/-) SCID mice. This effect is enhanced by antigen-specific activation of these T cells. Injection of recombinant active transforming growth factor-beta 2 into the ear of Tgfb1(-/-) SCID mice also results in the migration of Langerhans cells into the epidermis locally, but no epidermal Langerhans cells are seen after systemic injections of transforming growth factor-beta 2. Our results suggest that transforming growth factor-beta can act in paracrine as well as autocrine fashion to induce the differentiation of precursors into Langerhans cells. Furthermore, these results indicate that the relative roles of different transforming growth factor-beta isoforms in vivo may be influenced by their local availability and/or the regulation of their conversion from latent into active form.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11886525     DOI: 10.1046/j.0022-202x.2001.01550.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

Review 1.  The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.

Authors:  B Woodby; M Scott; J Bodily
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-11       Impact factor: 3.622

2.  Transforming growth factor-beta2 induces bronchial epithelial mucin expression in asthma.

Authors:  Hong Wei Chu; Silvana Balzar; Gregory J Seedorf; Jay Y Westcott; John B Trudeau; Phil Silkoff; Sally E Wenzel
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

3.  Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice.

Authors:  Poshala Aluwihare; Zhenyu Mu; Zhicheng Zhao; Dawen Yu; Paul H Weinreb; Gerald S Horan; Shelia M Violette; John S Munger
Journal:  J Cell Sci       Date:  2009-01-15       Impact factor: 5.285

4.  Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors.

Authors:  Keiji Yoshinaga; Hiroto Obata; Vladimir Jurukovski; Roberta Mazzieri; Yan Chen; Lior Zilberberg; David Huso; Jonathan Melamed; Petra Prijatelj; Vesna Todorovic; Branka Dabovic; Daniel B Rifkin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-20       Impact factor: 11.205

5.  Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice.

Authors:  Zhiwei Yang; Zhenyu Mu; Branka Dabovic; Vladimir Jurukovski; Dawen Yu; Joanne Sung; Xiaozhong Xiong; John S Munger
Journal:  J Cell Biol       Date:  2007-03-12       Impact factor: 10.539

6.  Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin.

Authors:  Kate Matthews; Cheng Mee Leong; Lindsay Baxter; Emma Inglis; Kankatsu Yun; B Thomas Bäckström; John Doorbar; Merilyn Hibma
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

7.  Autocrine/paracrine TGFbeta1 is required for the development of epidermal Langerhans cells.

Authors:  Daniel H Kaplan; Ming O Li; Matthew C Jenison; Warren D Shlomchik; Richard A Flavell; Mark J Shlomchik
Journal:  J Exp Med       Date:  2007-10-15       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.